Journal
ALZHEIMERS & DEMENTIA
Volume 16, Issue 7, Pages 1023-1030Publisher
WILEY
DOI: 10.1002/alz.12109
Keywords
Alzheimer's disease; autosomal-dominant Alzheimer's disease; baseline data; clinical trial; crenezumab; Alzheimer's Prevention Initiative; preclinical Alzheimer's disease; preclinical; prevention
Categories
Funding
- NIA [RF1 AG041705-01A1, R01 AG055444, P30 AG19610]
- Roche/Genentech
- Banner Alzheimer's Foundation
- Flinn Foundation
- Forget Me Not Initiative
- Nomis Foundation
- Colciencias
- University of Antioquia [1115-545-31651, 1115-657-4185]
- State of Arizona (Arizona Alzheimer's Consortium)
- National Institutes of Health
- Comite para el Desarrollo de la Investigacion (CODI-UdeA)
- National Institute of Aging [RF1 AG041705-01A1, R01 AG055444, UF1 AG046150, 1R01AG058468]
- Genentech/Roche
- Arizona Department of Health Services
- Alzheimer's Association
- FBRI
- GHR
- Avid/Lilly
- Novartis/Amgen
- National Institute on Aging
- National Institute of Neurologic Disorders
- GHR Foundation
- State of Arizona
- AstraZeneca
- Avanir
- Lilly
- Lundbeck
- Merck Co.
- Roche
- Takeda
- Amgen
- Avid
- Biogen
- Elan
- Functional Neuromodulation [f(nm)]
- GE
- Genentech
- Novartis
- Targacept
Ask authors/readers for more resources
Introduction: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo-controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60-year-old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non-carriers who receive placebo. Methods: Of the 252 enrolled, we present data on a total of 242 mutation carriers and non-carriers matched by age range, excluding data on 10 participants to protect participant confidentiality, genetic status, and trial integrity. Results: We summarize demographic, clinical, cognitive, and behavioral data from 167 mutation carriers and 75 non-carriers, 30 to 53 years of age. Carriers were significantly younger than non-carriers ((mean age +/- SD) 37 +/- 5 vs 42 +/- 6), had significantly lower Mini Mental Status Exam (MMSE) scores (28.8 +/- 1.4vs 29.2 +/- 1.0), and had consistently lower memory scores. Discussion: Although PSEN1 E280A mutation carriers in the Trial are cognitively unimpaired, they have slightly lower MMSE and memory scores than non-carriers. Their demographic characteristics are representative of the local population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available